Long-lasting alterations in adipose tissue density and adiponectin production in people living with HIV after thymidine analogues exposure

Table 3 Association between cumulative periods of exposure to and time since discontinuation of TA and ddI with adipose tissue density

	VAT density	p-value	SAT density	p-value
	Adjusted β* [95% CI]		Adjusted β** [95% CI]
Cumulative time of exposure to TA and/or ddI
<3.6 years	Ref		Ref
3.6–6.3 years	1.0 [−0.5;2.5]	0.198	−1.0 [−2.4;0.3]	0.141
6.4–9.2 years	0.2 [− 1.3;1.8]	0.770	−2.8 [−4.2;-1.4]	< 0.001
>9.2 years	− 0.5 [− 2.1;1.2]	0.578	−2.3 [−3.8;-0.9]	0.001
Time since discontinuation of TA and/or ddI
<8.1 years	Ref		Ref
8.1–9.6 years	−0.3 [− 1.8;1.2]	0.702	−0.0 [− 1.4;1.4]	0.965
9.7–10.7 years	1.4 [− 0.1;2.9]	0.074	0.4 [− 1.1;1.8]	0.593
>10.7	0.6 [− 1.0;2.1]	0.460	−0.6 [− 2.0;0.9]	0.431

β coefficients represent the degree of change in HU of VAT and SAT, respectively, associated with each level of the explanatory variables
Abbreviations: visceral adipose tissue, VAT; subcutaneous adipose tissue, SAT; thymidine nucleoside analog reverse-transcriptase inhibitors, TA; confidence interval, CI
All the models were adjusted for age, sex, origin, physical activity, smoking, BMI, cumulative time of exposure to TA and/or ddI, time since discontinuation of TA and/or ddI, VAT area* (or SAT area**)

ISSN: 1471-2334